Efficacy and safety of tacrolimus therapy for lupus nephritis: A systematic review of clinical trials

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The aim of this study was to assess the efficacy and safety of tacrolimus for the treatment of lupus nephritis (LN). A systematic review of clinical trials on tacrolimus in LN was conducted. Seven studies met the review inclusion criteria. Two studies were case-control studies, and five studies were open-label trials. One randomized controlled trial (RCT) found that tacrolimus significantly improved lupus nephritis disease activity index (LNDAI) as compared with a placebo, but no difference was observed between these two groups in terms of treatment-related adverse events. The other case-control study compared tacrolimus with standard protocols of oral cyclophosphamide or azathioprine for the treatment of membranous LN and found that efficacies were similar. All five open-label prospective studies concluded that tacrolimus is safe and effective as an induction and maintenance therapy for LN or for the treatment of LN with persistent proteinuria that failed to respond to prednisolone and immunosuppressants. In conclusion, this systematic review shows that tacrolimus may be effective as an induction and maintenance therapy for LN or as a treatment for LN with persistent proteinuria despite gold standard treatment. However, further RCTs are needed to compare tacrolimus with standard regimens for the treatment of LN.

Original languageEnglish
Pages (from-to)636-640
Number of pages5
JournalLupus
Volume20
Issue number6
DOIs
Publication statusPublished - 2011 May 1

Fingerprint

Lupus Nephritis
Tacrolimus
Clinical Trials
Safety
Therapeutics
Proteinuria
Case-Control Studies
Azathioprine
Immunosuppressive Agents
Prednisolone
Cyclophosphamide
Randomized Controlled Trials
Placebos
Prospective Studies

Keywords

  • lupus nephritis
  • systematic review
  • tacrolimus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Efficacy and safety of tacrolimus therapy for lupus nephritis : A systematic review of clinical trials. / Lee, Young Ho; Lee, H. S.; Choi, Sungjae; Ji, Jong Dae; Song, Gwan Gyu.

In: Lupus, Vol. 20, No. 6, 01.05.2011, p. 636-640.

Research output: Contribution to journalArticle

@article{c1cdb983085c4f06b863f7f03a02325b,
title = "Efficacy and safety of tacrolimus therapy for lupus nephritis: A systematic review of clinical trials",
abstract = "The aim of this study was to assess the efficacy and safety of tacrolimus for the treatment of lupus nephritis (LN). A systematic review of clinical trials on tacrolimus in LN was conducted. Seven studies met the review inclusion criteria. Two studies were case-control studies, and five studies were open-label trials. One randomized controlled trial (RCT) found that tacrolimus significantly improved lupus nephritis disease activity index (LNDAI) as compared with a placebo, but no difference was observed between these two groups in terms of treatment-related adverse events. The other case-control study compared tacrolimus with standard protocols of oral cyclophosphamide or azathioprine for the treatment of membranous LN and found that efficacies were similar. All five open-label prospective studies concluded that tacrolimus is safe and effective as an induction and maintenance therapy for LN or for the treatment of LN with persistent proteinuria that failed to respond to prednisolone and immunosuppressants. In conclusion, this systematic review shows that tacrolimus may be effective as an induction and maintenance therapy for LN or as a treatment for LN with persistent proteinuria despite gold standard treatment. However, further RCTs are needed to compare tacrolimus with standard regimens for the treatment of LN.",
keywords = "lupus nephritis, systematic review, tacrolimus",
author = "Lee, {Young Ho} and Lee, {H. S.} and Sungjae Choi and Ji, {Jong Dae} and Song, {Gwan Gyu}",
year = "2011",
month = "5",
day = "1",
doi = "10.1177/0961203310389486",
language = "English",
volume = "20",
pages = "636--640",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety of tacrolimus therapy for lupus nephritis

T2 - A systematic review of clinical trials

AU - Lee, Young Ho

AU - Lee, H. S.

AU - Choi, Sungjae

AU - Ji, Jong Dae

AU - Song, Gwan Gyu

PY - 2011/5/1

Y1 - 2011/5/1

N2 - The aim of this study was to assess the efficacy and safety of tacrolimus for the treatment of lupus nephritis (LN). A systematic review of clinical trials on tacrolimus in LN was conducted. Seven studies met the review inclusion criteria. Two studies were case-control studies, and five studies were open-label trials. One randomized controlled trial (RCT) found that tacrolimus significantly improved lupus nephritis disease activity index (LNDAI) as compared with a placebo, but no difference was observed between these two groups in terms of treatment-related adverse events. The other case-control study compared tacrolimus with standard protocols of oral cyclophosphamide or azathioprine for the treatment of membranous LN and found that efficacies were similar. All five open-label prospective studies concluded that tacrolimus is safe and effective as an induction and maintenance therapy for LN or for the treatment of LN with persistent proteinuria that failed to respond to prednisolone and immunosuppressants. In conclusion, this systematic review shows that tacrolimus may be effective as an induction and maintenance therapy for LN or as a treatment for LN with persistent proteinuria despite gold standard treatment. However, further RCTs are needed to compare tacrolimus with standard regimens for the treatment of LN.

AB - The aim of this study was to assess the efficacy and safety of tacrolimus for the treatment of lupus nephritis (LN). A systematic review of clinical trials on tacrolimus in LN was conducted. Seven studies met the review inclusion criteria. Two studies were case-control studies, and five studies were open-label trials. One randomized controlled trial (RCT) found that tacrolimus significantly improved lupus nephritis disease activity index (LNDAI) as compared with a placebo, but no difference was observed between these two groups in terms of treatment-related adverse events. The other case-control study compared tacrolimus with standard protocols of oral cyclophosphamide or azathioprine for the treatment of membranous LN and found that efficacies were similar. All five open-label prospective studies concluded that tacrolimus is safe and effective as an induction and maintenance therapy for LN or for the treatment of LN with persistent proteinuria that failed to respond to prednisolone and immunosuppressants. In conclusion, this systematic review shows that tacrolimus may be effective as an induction and maintenance therapy for LN or as a treatment for LN with persistent proteinuria despite gold standard treatment. However, further RCTs are needed to compare tacrolimus with standard regimens for the treatment of LN.

KW - lupus nephritis

KW - systematic review

KW - tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=79956153771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956153771&partnerID=8YFLogxK

U2 - 10.1177/0961203310389486

DO - 10.1177/0961203310389486

M3 - Article

C2 - 21382917

AN - SCOPUS:79956153771

VL - 20

SP - 636

EP - 640

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 6

ER -